+
データを開く
-
基本情報
| 登録情報 | データベース: EMDB / ID: EMD-22015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| タイトル | Wt pig RyR1 in complex with apoCaM, EGTA condition (class 1 and 2, closed) | |||||||||
マップデータ | RyR1, FKBP12.6, CaM | |||||||||
試料 |
| |||||||||
キーワード | receptor / calcium / channel / complex / TRANSPORT PROTEIN-ISOMERASE-CALCIUM BINDING PROTEIN complex | |||||||||
| 機能・相同性 | 機能・相同性情報positive regulation of sequestering of calcium ion / negative regulation of calcium-mediated signaling / negative regulation of insulin secretion involved in cellular response to glucose stimulus / neuronal action potential propagation / negative regulation of release of sequestered calcium ion into cytosol / insulin secretion involved in cellular response to glucose stimulus / CaM pathway / Cam-PDE 1 activation / Sodium/Calcium exchangers / response to redox state ...positive regulation of sequestering of calcium ion / negative regulation of calcium-mediated signaling / negative regulation of insulin secretion involved in cellular response to glucose stimulus / neuronal action potential propagation / negative regulation of release of sequestered calcium ion into cytosol / insulin secretion involved in cellular response to glucose stimulus / CaM pathway / Cam-PDE 1 activation / Sodium/Calcium exchangers / response to redox state / Calmodulin induced events / Reduction of cytosolic Ca++ levels / Activation of Ca-permeable Kainate Receptor / CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde / 'de novo' protein folding / negative regulation of heart rate / Loss of phosphorylation of MECP2 at T308 / CREB1 phosphorylation through the activation of Adenylate Cyclase / CaMK IV-mediated phosphorylation of CREB / PKA activation / negative regulation of high voltage-gated calcium channel activity / Glycogen breakdown (glycogenolysis) / CLEC7A (Dectin-1) induces NFAT activation / Activation of RAC1 downstream of NMDARs / negative regulation of ryanodine-sensitive calcium-release channel activity / organelle localization by membrane tethering / mitochondrion-endoplasmic reticulum membrane tethering / autophagosome membrane docking / FK506 binding / negative regulation of calcium ion export across plasma membrane / regulation of cardiac muscle cell action potential / presynaptic endocytosis / Synthesis of IP3 and IP4 in the cytosol / regulation of cell communication by electrical coupling involved in cardiac conduction / Phase 0 - rapid depolarisation / calcineurin-mediated signaling / Negative regulation of NMDA receptor-mediated neuronal transmission / Unblocking of NMDA receptors, glutamate binding and activation / RHO GTPases activate PAKs / Ion transport by P-type ATPases / Uptake and function of anthrax toxins / regulation of ryanodine-sensitive calcium-release channel activity / Long-term potentiation / protein phosphatase activator activity / smooth muscle contraction / Calcineurin activates NFAT / Regulation of MECP2 expression and activity / DARPP-32 events / Smooth Muscle Contraction / detection of calcium ion / regulation of cardiac muscle contraction / catalytic complex / RHO GTPases activate IQGAPs / regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion / T cell proliferation / cellular response to interferon-beta / Protein methylation / calcium channel inhibitor activity / Activation of AMPK downstream of NMDARs / presynaptic cytosol / regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum / Ion homeostasis / eNOS activation / titin binding / Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation / sperm midpiece / release of sequestered calcium ion into cytosol / regulation of calcium-mediated signaling / voltage-gated potassium channel complex / calcium channel complex / FCERI mediated Ca+2 mobilization / substantia nigra development / sarcoplasmic reticulum membrane / regulation of heart rate / Ras activation upon Ca2+ influx through NMDA receptor / FCGR3A-mediated IL10 synthesis / Antigen activates B Cell Receptor (BCR) leading to generation of second messengers / calyx of Held / protein maturation / adenylate cyclase activator activity / sarcomere / VEGFR2 mediated cell proliferation / protein serine/threonine kinase activator activity / VEGFR2 mediated vascular permeability / regulation of cytokinesis / spindle microtubule / Translocation of SLC2A4 (GLUT4) to the plasma membrane / positive regulation of receptor signaling pathway via JAK-STAT / calcium channel regulator activity / peptidylprolyl isomerase / peptidyl-prolyl cis-trans isomerase activity / calcium-mediated signaling / RAF activation / Transcriptional activation of mitochondrial biogenesis / response to calcium ion / cellular response to type II interferon / Stimuli-sensing channels / G2/M transition of mitotic cell cycle / Z disc / long-term synaptic potentiation 類似検索 - 分子機能 | |||||||||
| 生物種 | ![]() Homo sapiens (ヒト) | |||||||||
| 手法 | 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.8 Å | |||||||||
データ登録者 | Woll KW / Haji-Ghassemi O | |||||||||
| 資金援助 | 1件
| |||||||||
引用 | ジャーナル: Nat Commun / 年: 2021タイトル: Pathological conformations of disease mutant Ryanodine Receptors revealed by cryo-EM. 著者: Kellie A Woll / Omid Haji-Ghassemi / Filip Van Petegem / ![]() 要旨: Ryanodine Receptors (RyRs) are massive channels that release Ca from the endoplasmic and sarcoplasmic reticulum. Hundreds of mutations are linked to malignant hyperthermia (MH), myopathies, and ...Ryanodine Receptors (RyRs) are massive channels that release Ca from the endoplasmic and sarcoplasmic reticulum. Hundreds of mutations are linked to malignant hyperthermia (MH), myopathies, and arrhythmias. Here, we explore the first MH mutation identified in humans by providing cryo-EM snapshots of the pig homolog, R615C, showing that it affects an interface between three solenoid regions. We also show the impact of apo-calmodulin (apoCaM) and how it can induce opening by bending of the bridging solenoid, mediated by its N-terminal lobe. For R615C RyR1, apoCaM binding abolishes a pathological 'intermediate' conformation, distributing the population to a mixture of open and closed channels, both different from the structure without apoCaM. Comparisons show that the mutation primarily affects the closed state, inducing partial movements linked to channel activation. This shows that disease mutations can cause distinct pathological conformations of the RyR and facilitate channel opening by disrupting interactions between different solenoid regions. | |||||||||
| 履歴 |
|
-
構造の表示
| ムービー |
ムービービューア |
|---|---|
| 構造ビューア | EMマップ: SurfView Molmil Jmol/JSmol |
| 添付画像 |
-
ダウンロードとリンク
-EMDBアーカイブ
| マップデータ | emd_22015.map.gz | 62.8 MB | EMDBマップデータ形式 | |
|---|---|---|---|---|
| ヘッダ (付随情報) | emd-22015-v30.xml emd-22015.xml | 18.7 KB 18.7 KB | 表示 表示 | EMDBヘッダ |
| 画像 | emd_22015.png | 222.6 KB | ||
| Filedesc metadata | emd-22015.cif.gz | 7.9 KB | ||
| アーカイブディレクトリ | http://ftp.pdbj.org/pub/emdb/structures/EMD-22015 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-22015 | HTTPS FTP |
-関連構造データ
-
リンク
| EMDBのページ | EMDB (EBI/PDBe) / EMDataResource |
|---|---|
| 「今月の分子」の関連する項目 |
-
マップ
| ファイル | ダウンロード / ファイル: emd_22015.map.gz / 形式: CCP4 / 大きさ: 421.9 MB / タイプ: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注釈 | RyR1, FKBP12.6, CaM | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 投影像・断面図 | 画像のコントロール
画像は Spider により作成 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ボクセルのサイズ | X=Y=Z: 1.09 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 密度 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 対称性 | 空間群: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 詳細 | EMDB XML:
CCP4マップ ヘッダ情報:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-添付データ
-
試料の構成要素
-全体 : ryanodine receptor-FKBP1B-Calmodulin complex
| 全体 | 名称: ryanodine receptor-FKBP1B-Calmodulin complex |
|---|---|
| 要素 |
|
-超分子 #1: ryanodine receptor-FKBP1B-Calmodulin complex
| 超分子 | 名称: ryanodine receptor-FKBP1B-Calmodulin complex / タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#3 |
|---|
-超分子 #2: ryanodine receptor
| 超分子 | 名称: ryanodine receptor / タイプ: complex / ID: 2 / 親要素: 1 / 含まれる分子: #2 |
|---|---|
| 由来(天然) | 生物種: ![]() |
-超分子 #3: FKBP1B
| 超分子 | 名称: FKBP1B / タイプ: complex / ID: 3 / 親要素: 1 / 含まれる分子: #1 |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
-超分子 #4: Calmodulin
| 超分子 | 名称: Calmodulin / タイプ: complex / ID: 4 / 親要素: 1 / 含まれる分子: #3 |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
-分子 #1: Peptidyl-prolyl cis-trans isomerase FKBP1B
| 分子 | 名称: Peptidyl-prolyl cis-trans isomerase FKBP1B / タイプ: protein_or_peptide / ID: 1 / コピー数: 4 / 光学異性体: LEVO / EC番号: peptidylprolyl isomerase |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
| 分子量 | 理論値: 11.939562 KDa |
| 組換発現 | 生物種: ![]() |
| 配列 | 文字列: SNAGVEIETI SPGDGRTFPK KGQTCVVHYT GMLQNGKKFD SSRDRNKPFK FRIGKQEVIK GFEEGAAQMS LGQRAKLTCT PDVAYGATG HPGVIPPNAT LIFDVELLNL E UniProtKB: Peptidyl-prolyl cis-trans isomerase FKBP1B |
-分子 #2: Ryanodine Receptor
| 分子 | 名称: Ryanodine Receptor / タイプ: protein_or_peptide / ID: 2 / コピー数: 4 / 光学異性体: LEVO |
|---|---|
| 由来(天然) | 生物種: ![]() |
| 分子量 | 理論値: 422.853312 KDa |
| 配列 | 文字列: QFLRTDDEVV LQCNATVLKE QLKLCLAAEG FGNRLCFLEP TSNAQNVPPD LAICCFVLEQ SLSVRALQEM LANTVEAGHR TLLYGHAIL LRHAHSGMYL SCLTTSRSMT DKLAFDVGLQ EDATGEACWW TTHPASKQRS EGEKVRVGDD LILVSVSSER Y LHLSTLQV ...文字列: QFLRTDDEVV LQCNATVLKE QLKLCLAAEG FGNRLCFLEP TSNAQNVPPD LAICCFVLEQ SLSVRALQEM LANTVEAGHR TLLYGHAIL LRHAHSGMYL SCLTTSRSMT DKLAFDVGLQ EDATGEACWW TTHPASKQRS EGEKVRVGDD LILVSVSSER Y LHLSTLQV DASFMQTLWN MNPICSGCEE GYVTGGHVLR LFHGHMDECL TISPADSDDQ RRLVYYEGGS VCTHARSLWR LE PLRISWS GSHLRWGQPL RIRHVTTGRY LALIEDQGLV VVDASKAHTK ATSFCFRISK EKLKRDVEGM GPPEIKYGES LCF VQHVAS GLWLTYAALK KKAILHQEGH MDDALSLTRC QQEESQAARM IYSTAGLYNH FIKGLDSFSG KPRGSGAPAG TALP LEGVI LSLQDLIGYF EPPSEELQHE EKQSKLRSLR NRQSLFQEEG MLSLVLNCID RLNVYTTAAH FAEFAGEEAA ESWKE IVNL LYEILASLIR GNRANCALFS NNLDWLVSKL DRLEASSGIL EVLYCVLIES PEVLNIIQEN HIKSIISLLD KHGRNH KVL DVLCSLCVCN GVAVRSNQDL ITENLLPGRE LLLQTNLINY VTSIRPNIFV GRAEGTTQYS KWYFEVMVDE VVPFLTA QA THLRVGWALT EGYSPYPGGG EGWGGNGVGD DLYSYGFDGL HLWTGHVPRL VTSPGQHLLA PEDVVSCCLD LSVPSISF R INGCPVQGVF EAFNLNGLFF PVVSFSAGVK VRFLLGGRHG EFKFLPPPGY APCHEAVLPR ERLRLEPIKE YRREGPRGP HLVGPSRCLS HTDFVPCPLP PHLERIREKL AENIHELWAL TRIEQGWTYG PVRDDNKRLH PCLVDFHSLP EPERNYNLQM SGETLKTLL ALGCHVGMAD EKAEDNLRKT KLPKTYMMSN GYKPAPLDLS HVRLTPAQTT LVDRLAENGH NVWARDRVAQ G WSYSAVQD IPARRNPRLV PYRLLDEATK RSNRDSLCQA VRTLLGYGYN IERVRIFRAE KSYAVQSGRW YFEFEAVTTG EM RVGWARP ELRPDVELGA DELAYVFNGH RGQRWHLGSE LFGRPWQSGD VVGCMIDLTE NTIIFTLNGE VLMSDSGSET AFR DIEVGD GFLPVCSLGP GQVGHLNLGQ DVSSLRFFAI CGLQEGFEPF AINMQRPVTT WFSKSLPQFE AVPLEHPHYE VSRV DGTVD TPPCLRLTHR SLVEMLFLRL SLPVQFHQLN TTTYYYSVRV FAGQEPSCVW VGWVTPDYHQ HDMNFDLTKV RAVTV TMGD NIHSSLKCSN CYMVWGGDFV SHTDLVIGCL VDLATGLMTF TANGKESNTF FQVEPNTKLF PAVFVLPTHQ NVIQFE LGK QKNIMPLSAA MFLSERKNPA PQCPPRLEMQ MLMPVSWSRM PNHFLRVETR RAGERLGWAV QCQEPLTMMA LHIPEEN RC MDILELSERL DLQQFHSHTL RLYRAVCALG NNRVAHALCS HVDQAQLLHA LEDAHLPGPL RAGYYDLLIS IHLESACR S RRSMLSEYIV PLTPETRAIT LFPPRRHGLP GVGVTTSLRP PHHFSAPCFV AALPEAPARL SPSIPLEALR DKALRMLGE AVRDGGQHAR DPVGGSVEFQ FVPVLKLVST LLVMGIFGDE DVKQILKMIE PEVEEGLLQM KLPESVKLQM CNLLEYFCDQ ELQHRVESL AAFAERYVDK LQANQRDRYG ILMKAFTMTA AETARRTREF RSPPQEQINM LLHFKPLPDE IRQDLLEFHQ D LLTHCGIQ LQSLQELVSH TVVRWAQEDF VQSPELVRAM FSLLHRQYDG LGELLRALPR AYTISPSSVE DTMSLLECLG QI RSLLIVQ MGPQEENLMI QSIGNIMNNK VFYQHPNLMR ALGMHETVME VMVNVLGKEI RFPKMVTSCC RFLCYFCRIS RQN QRSMFD HLSYLLENSG IGLGMQGSTP LDVAAASVID NNELALALQE QDLEKVVSYL AGCGLQSYPD IGWNPCGGER YLDF LRFAV FVNGESVEEN ANVVVRLLIR KPECFGPALR GEGGSGLLAT IEEAIRISEH LGHAIMSFYA ALIDLLGRCA PEMHL IQAG KGEALRIRAI LRSLVPLDDL VGIISLPKMS ASFVPDHKAS MVLFLDRVYG IENAAFLLHV LDVGFLPDMR AAATFS TTE MALALNRYLC LAVLPLITKC APLFAMVDSM LHTVYRLSRG RSLTKAQRDV IEECLMALCR YIRPSMLQHL LRRLVFD VP (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)AADPRPVET LNVIIPEKLD SFINKFAEYT HEKWAFDKIQ NNWSYGENID EELKTHPMLR PYKTFSEKDK EIYRWP IKE SLKAMIAWEW TIEKAREGEY NPQPPDLSGV TLSRELQAMA EQLAENYHNT WGRKKKQELE AKGGGTHPLL VPYDTLT AK EKARDREKAQ ELLKFLQMNG YAVTR(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)PLLIRY VDNN RAHWL TEPNPSAEEL FRMVGEIFIY WSK(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)RRAVVAC FRMTPLYNLP THRACNMFLE SYKAAWILTE DHS FEDRMI DDLSKAGEQE EEEEEVEEKK PDPLHQLVLH FSRTALTEKS KLDEDYLYMA YADIMAKSCH LSFEEKEMEK QRLL YQQAR LHNRGAAEMV LQMISACKGE TGAMVSSTLK LGISILNGGN ADVQQKMLDY LKDKKEVGFF QSIQALMQTC SVLDL NAFE RQNKAEGLGM VNEDGTVEKV MADDEFTQDL FRFLQLLCEG HNNDFQNYLR TQTGNTTTIN IIICTVDYLL RLQESI SDF YWYYSGKDVI EEQGKRNFSK AMSVAKQVFN SLTEYIQGPC TGNQQSLAHS RLWDAVVGFL HVFAHMMMKL AQDSSQI EL LKELLDLQKD MVVMLLSLLE GNVVNGMIAR QMVDMLVESS SNVEMILKFF DMFLKLKDIV GSEAFQDYVT DPRGLISK K DFQK(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) EFANRFQEPA RDIGFNVAVL LTNLSEHVPH DPRLRNFLEL AESIL EYFR PYLGRIEIMG ASRRIERIYF EISETNRAQW EMPQVKESKR QFIFDVVNEG GESEKMELFV SFCEDTIFEM QIAAQI (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)EVQRV KFLNYLSRNF YTLRFLALFL AFAINFILLF YKVSDSPPVY YFLEESTGYM EPALRCLSLL HTLVAFLCII GYNCLKVPL VIFKREKELA RKLEFDGLYI TEQPEDDDVK GQWDRLVLNT PSFPSNYWDK FVKRKVLDKH GDIYGRERIA E IDVKYQIW KFGVIFTDNS FLYLGWYMVM SLLGHYNNFF FAAHLLDIAM GVKTLRTILS SVTHNGKQLV MTVGLLAVVV YL YTVVAFN FFRKFYNKDM KCDDMMTCYL FHMYVGVRAG GGIGDEIEDP AGDEYELYRV VFDITFFFFV IVILLAIIQG LII DAFGEL RDQQEQVRED METKCFICGI GSDYFDTTPH RFETHTLEEH NLANYMFFLM YLINKDETEH TGQESYVWKM YQER CWDFF PAGDCFRKQY EDQLS |
-分子 #3: Calmodulin-1
| 分子 | 名称: Calmodulin-1 / タイプ: protein_or_peptide / ID: 3 / コピー数: 4 / 光学異性体: LEVO |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
| 分子量 | 理論値: 16.521094 KDa |
| 組換発現 | 生物種: ![]() |
| 配列 | 文字列: DQLTEEQIAE FKEAFSLFDK DGDGTITTKE LGTVMRSLGQ NPTEAELQDM INEVDADGNG TIDFPEFLTM MARKMKDTDS EEEIREAFR VFDKDGNGYI SAAELRHVMT NLGEKLTDEE VDEMIREADI DGDGQVNYEE FVQMMTA UniProtKB: Calmodulin-1 |
-分子 #4: ZINC ION
| 分子 | 名称: ZINC ION / タイプ: ligand / ID: 4 / コピー数: 4 / 式: ZN |
|---|---|
| 分子量 | 理論値: 65.409 Da |
-実験情報
-構造解析
| 手法 | クライオ電子顕微鏡法 |
|---|---|
解析 | 単粒子再構成法 |
| 試料の集合状態 | particle |
-
試料調製
| 緩衝液 | pH: 7.5 |
|---|---|
| グリッド | 詳細: unspecified |
| 凍結 | 凍結剤: ETHANE |
-
電子顕微鏡法
| 顕微鏡 | FEI TITAN KRIOS |
|---|---|
| 撮影 | フィルム・検出器のモデル: FEI FALCON III (4k x 4k) 平均電子線量: 50.0 e/Å2 |
| 電子線 | 加速電圧: 300 kV / 電子線源: FIELD EMISSION GUN |
| 電子光学系 | 照射モード: OTHER / 撮影モード: DIFFRACTION |
| 実験機器 | ![]() モデル: Titan Krios / 画像提供: FEI Company |
-
画像解析
| 初期モデル | モデルのタイプ: PDB ENTRY |
|---|---|
| 最終 再構成 | 想定した対称性 - 点群: C4 (4回回転対称) / 解像度のタイプ: BY AUTHOR / 解像度: 3.8 Å / 解像度の算出法: FSC 0.143 CUT-OFF / ソフトウェア - 名称: PHENIX (ver. dev-3714) / 使用した粒子像数: 44957 |
| 初期 角度割当 | タイプ: MAXIMUM LIKELIHOOD |
| 最終 角度割当 | タイプ: MAXIMUM LIKELIHOOD |
ムービー
コントローラー
万見について



キーワード
Homo sapiens (ヒト)
データ登録者
引用
UCSF Chimera






































Z (Sec.)
Y (Row.)
X (Col.)























